Orchard Therapeutics (ORTX) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ORTX shares.
View ORTX analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued twelve-month price objectives for Orchard Therapeutics' shares. Their ORTX share price forecasts range from $15.00 to $37.00. On average, they anticipate the company's stock price to reach $26.00 in the next year. This suggests a possible upside of 409.8% from the stock's current price.
View analysts price targets for ORTX or view top-rated stocks among Wall Street analysts.

Orchard Therapeutics' stock was trading at $3.71 at the start of the year. Since then, ORTX shares have increased by 37.5% and is now trading at $5.10.
View the best growth stocks for 2023 here.

Orchard Therapeutics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 80,600 shares, a decrease of 25.4% from the April 30th total of 108,100 shares. Based on an average trading volume of 72,600 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.5% of the company's stock are sold short.
View Orchard Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ORTX earnings forecast.

Orchard Therapeutics plc (NASDAQ:ORTX) announced its quarterly earnings results on Monday, May, 15th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($1.61) by $1.49. The company had revenue of $1.24 million for the quarter, compared to analysts' expectations of $6.48 million. Orchard Therapeutics had a negative trailing twelve-month return on equity of 105.36% and a negative net margin of 673.87%.

Orchard Therapeutics shares reverse split before market open on Friday, March 10th 2023. The 1-10 reverse split was announced on Friday, March 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

(ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

Orchard Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (10.46%), CHI Advisors LLC (4.27%), Temasek Holdings Private Ltd (2.35%), Citigroup Inc. (0.91%), Acadian Asset Management LLC (0.65%) and Platinum Investment Management Ltd. (0.65%). Insiders that own company stock include Bobby Gaspar, Fmr Llc and Frank E Thomas.
View institutional ownership trends.

Shares of ORTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ORTX stock can currently be purchased for approximately $5.10.

Orchard Therapeutics (NASDAQ:ORTX) has a market capitalization of $93.84 million and generates $22.66 million in revenue each year. The company earns $-150,660,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis.

The company employs 259 workers across the globe.

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The official website for the company is www.orchard-tx.com. The company can be reached via phone at 442038088286 or via email at investors@orchard-tx.com.